Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Pharma And Distributors Suffer From Essential Drug List System And Price Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Morgan Stanley analysts poured cold water on investor hopes in Hong Kong by downgrading pharma and distribution sectors in a July 7 research note.
Advertisement

Related Content

After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
After A Record Year, China Healthcare IPOs Have Endured A Tough 2011
In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model
Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected

Topics

Advertisement
UsernamePublicRestriction

Register

PS072500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel